Early use of daptomycin versus vancomycin for methicillin-resistant staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: A matched cohort study

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1562-1569

  Murray, Kyle P ^a   Zhao, Jing J ^a   Davis, Susan L ^b   Kullar, Ravina ^b   Kaye, Keith S ^b   Lephart, Paul ^a   Rybak, Michael J ^a,b  

^a DETROIT MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

bacteremia; daptomycin; methicillin resistant Staphylococcus aureus; vancomycin

Indexed keywords

AMINOGLYCOSIDE; CREATININE; DAPTOMYCIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BONE INFECTION; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; DECUBITUS; DIABETES MELLITUS; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SUBSTITUTION; ENDOCARDITIS; FEMALE; HEALTH CARE COST; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS ARTHRITIS; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NEOPLASM; NEPHROTOXICITY; PERSISTENT INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL PATIENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

BACTEREMIA; DAPTOMYCIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DAPTOMYCIN; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84877309474     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit112     Document Type: Article

References (26)

1. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staph-ylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-91.
2. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46:2950-4.
3. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011; 37:219-24.
4. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylo-coccus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20.
5. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
6. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
7. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylo-coccus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81.
8. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of van-comycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71.
9. Wi YM, Kim JM, Joo EJ, et al. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylo-coccus aureus bacteraemia. Int J Antimicrob Agents 2012; 40:108-13.
10. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010; 65:1015-8.
11. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7.
12. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicil-lin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
13. Hill PC, Birch M, Chambers S, et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J 2001; 31:97-103.
14. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacoki-netics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 16:513-8.
15. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-7.
16. Cubicin package insert. Cubist Pharmaceuticals, Inc, Lexington, MA. 2010.
17. Kullar R, Davis SL, Kaye KS, et al. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacother-apy 2013; 33:3-10.
18. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vanco-mycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51-8.
19. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methi-cillin-resistant isolates. J Antimicrob Chemother 2008; 62:1413-21.
20. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123:631-7.
21. Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation-a study of 521 patients in Germany. J Infect 2009; 59:232-9.
22. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococ-cus aureus. New Engl J Med 2006; 355:653-65.
23. Marconescu P, Graviss EA, Musher DM. Rates of killing of methicil-lin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and te-lavancin compared to that of vancomycin. Scand J Infect Dis 2012; 44:620-2.
24. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177-80.
25. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31:527-36.
26. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012; 32:195-201.